TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03673384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infrared-C ray irradiation
Description: Infrared-C irradiation by hot compress with a powered heating compress

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eye mask
Description: infrared-C irradiation by hot compress with a powered heating eye mask

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xyzal Oral Product
Description: used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyzal Oral Product
Description: used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Furoate
Description: used to treat seasonal and perennial allergic rhinitis. It also helps to reduce the symptoms of seasonal allergic rhinitis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate
Description: used to treat seasonal and perennial allergic rhinitis. It also helps to reduce the symptoms of seasonal allergic rhinitis.
Study: NCT00644371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab Tiuxetan (Zevalin)
Description: Conditioning Regimen~1. Rituximab, 250 mg/m2 on days -21 and -14.~2. Ibritumomab tiuxetan (Zevalin): 0.4 mCi/kg (14.8 MBq/kg). Maximum: 32 mCi on day -14.~Chemotherapy:~* Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~* Melphalan 70 mg/m2/day on days -3 and -2 as a 15-min infusion.~Chemotherapy for relapsing patients after autologous transplantation including melphalan over the last 6 months:~* Thiotepa 5 mg/kg over 4 hours every 12 hours on day -8.~* Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~* Melphalan 70 mg/m2/day on day -2 as a 15-min infusion.
Study: NCT02101320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRECAM
Description: using the camera during the surgery
Study: NCT03624270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral arsenic Trioxide, ATRA and ascorbic acid
Description: Oral arsenic trioxide-based frontline induction, consolidation and maintenance will be provided to patients with newly diagnosed acute promyelocytic leukemia.
Study: NCT04512027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolectin-M; a (1-6)-alpha-D-Mannopyranose class
Description: A treatment to decrease viral load, detected through digital droplet PCR, in mild to moderate cases of RT-PCR positive COVID-19

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Currently approved standard of care for patients without symptoms requiring hospitalisation will be provided to all.
Study: NCT03273127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol
Description: A β2-adrenoceptor agonists, produce smooth muscle relaxation in the airways and improves lung function.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Abediterol matching placebo without any pharmacological activity.
Study: NCT00185211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
Study: NCT00265083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: golimumab
Description: 100 mg sc injections every 4 wks from wk 0 up to 5 yrs

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab (CNTO 148); placebo
Description: SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: golimumab
Description: 50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
Study: NCT03916237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home remediation
Description: Low level home remediation according to previously established protocol (Kercsmar CM, Dearborn DG, Schluchter M, et al. Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources. Environ Health Perspect. 2006;114(10):1574-80)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home remediation
Description: Low level home remediation according to previously established protocol (Kercsmar CM, Dearborn DG, Schluchter M, et al. Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources. Environ Health Perspect. 2006;114(10):1574-80)
Study: NCT01841359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: See description above (arm description).
Study: NCT04393805

Intervention type: DRUG
Intervention: Low Molecular Weight Heparin
Description: Thromboprophylaxis with Low Molecular Weight Heparin, mostly enoxaparin

Intervention type: DRUG
Intervention: Low Molecular Weight Heparin
Description: Thromboprophylaxis with Low Molecular Weight Heparin, mostly enoxaparin
Study: NCT00721461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V930
Description: Intramuscular injection of phosphate buffered saline solution will be given and within 2 - 5 minutes will be followed by an electrostimulation pulse with the MedPulser DDS in the deltoid muscle of the right arm. 15 days later, the same procedure will take place using the left arm.
Study: NCT03908983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kalios Implant
Description: KALIOS is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of KALIOS is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
Study: NCT03935659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Pressure Wound Therapy
Description: Investigators will be using a Negative Pressure Wound Therapy Powered Suction Pump on primarily closed groin wounds after open common femoral artery exposure, The Negative pressure dressing will be applied in a sterile fashion in the operating room. The negative pressure dressing will be removed at day 5 postoperatively, or at discharge, whichever occurs first.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Care
Description: Standard sterile gauze coverage of the primarily closed groin wound.
Study: NCT03524937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MELATONIN (HIGH DOSE)
Description: Enteral melatonin (3mg) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MELATONIN (LOW DOSE)
Description: Enteral melatonin (0.3mg ) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days.
Study: NCT00528437

Intervention type: DRUG
Group type: OTHER
Intervention: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
Description: 13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
Study: NCT04627220

Intervention type: DIAGNOSTIC_TEST
Intervention: taken venous sample
Description: Venous blood samples taken during the operation and at the 48th hour after the operation will be examined after appropriate procedures.

Intervention type: DIAGNOSTIC_TEST
Intervention: taken venous sample
Description: Venous blood samples taken during the operation and at the 48th hour after the operation will be examined after appropriate procedures.
Study: NCT04275661

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound (US) bi-level erector spinae block
Description: nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) bi-level erector spinae block
Description: nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) bi-level erector spinae block
Description: nerve block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levobupivacaine
Description: 20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: 20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle
Study: NCT02624973

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy breast/chest wall + regional lymph nodes
Study: NCT04275661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: 20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 2 mg /kg ketamine.injected into fascial plane deep to erector spinae muscle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 2mg/kg Magnesium Sulfate .injected into fascial plane deep to erector spinae muscle
Study: NCT03372369

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: View CDC Poster
Description: The poster designed by the CDC to explain contraceptive effectiveness.
Study: NCT02624973

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy breast/chest wall + regional lymph nodes

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy breast/chest wall + regional lymph nodes
Study: NCT03372369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: View Patient-Centered Poster
Description: The poster designed by the research team to explain contraceptive effectiveness. This poster was developed through cognitive interviews with 26 North Carolina women, and the final version of this poster was found to be more useful, acceptable, and attractive than the CDC poster by the majority of women participating.
Study: NCT02094937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate 100 mcg
Description: FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 250 mcg
Description: FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 100 mcg
Description: FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate Placebo
Description: Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate Placebo
Description: Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate Placebo
Description: Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
Study: NCT04317781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tagraxofusp-erzs
Description: Given IV
Study: NCT00353938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-methylenedioxymethamphetamine (125 mg)
Description: Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3,4-methyelendioxymethamphetamine (25 mg)
Description: Participants will receive a 25 mg MDMA orally, and if investigator and participant agree, 2.5 hours later they will receive 12.5 mg MDMA orally.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Non-directive therapy performed by a team of two co-therapists

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Non-directive therapy performed by a team of two co-therapists
Study: NCT02624973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Study: NCT02281630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04645238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: Static hamstring stretching exercise lasting 30 seconds and 10 repetitions under the supervision of the physiotherapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF Stretching
Description: PNF hold-relax stretching technique that consists of 10 seconds isometric contraction, 30 seconds hamstring stretching and 10 repetitions under the supervision of the physiotherapist
Study: NCT04537702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Streamlined Education
Description: After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. This video will be made with the assistance of Duke University genetic counselors and gynecologic oncology providers. It will consist of a discussion of genes and mutations, the recommendation of universal testing for high grade epithelial ovarian cancer, a review of genes associated with ovarian cancer predisposition, the possibility of uncertain results including variants of undetermined significance, the potential for undetected mutations in known or unknown cancer susceptibility genes, the potential impact on personal treatment and on family members, the possibility of genetic discrimination and the legal protection of genetic information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Education
Description: The TG subjects will then meet with the genetic counselor at the previously scheduled appointment time. During this visit, they will receive approximately thirty to sixty minutes of counseling regarding genetic testing and potential results. The discussion is based on the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines of informed consent for genetic testing. After counseling, participants will be given the option to undergo a multi-gene panel genetic test either via saliva or blood sample. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice of the clinical genetic service at DCI, patients will also be asked to provide consent for somatic tumor testing of surgical specimen (non-cytologic).
Study: NCT03256383

Intervention type: DEVICE
Intervention: Lead testing
Description: Fingerstick

Intervention type: DEVICE
Intervention: Lead testing
Description: Fingerstick
Study: NCT03256383

Intervention type: DEVICE
Intervention: Lead testing
Description: Fingerstick
Study: NCT00618423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
Study: NCT01623830

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Exposure Therapy
Description: Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
Study: NCT04448691

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CCTA
Description: requested follow up CCTA
Study: NCT01792284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study: NCT02624973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant letrozole (postmenopausal women)
Study: NCT01792284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
Study: NCT02624973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant letrozole (postmenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant letrozole (postmenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant letrozole (postmenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant letrozole (postmenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant letrozole (postmenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen + goserelin (premenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen + goserelin (premenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen + goserelin (premenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen + goserelin (premenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen + goserelin (premenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen + goserelin (premenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant palbociclib (if palbociclib given neoadjuvant)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Epirubicin+ Cyclophosphamide
Study: NCT01792284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
Study: NCT02279576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800mg/day continuously administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
Study: NCT00803946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Tablets, 800 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Tablets, 800 mg
Study: NCT03124381

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cleanser, Acne Mask
Description: A facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleanser, Gel-Cream, Acne Mask
Description: A facial cleanser will be used twice daily (morning and evening). In the evening after cleansing, the gel-cream will be applied full face and allowed to dry before the light therapy mask is used for 10 minutes.
Study: NCT05678985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Move
Description: As described under study arm description.
Study: NCT03995303

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCP and home-delivered meals
Description: The dietitian (Ph.D. student) will perform an individual nutritional assessment focusing on dietary intake, activity level and weight of each participant, as a basis for developing an individualized nutrition care plan consistent with estimated nutritional requirements and nutritional rehabilitation goals. Total fluid, energy- and protein requirements will be estimated for each patient. Giving the group free food to fulfill protein-and energy needs.